

hotline will enable the public to obtain information about a particular advisory committee by using the committee's 5-digit number. Information in the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made.

MEETINGS: The following advisory committee meetings are announced:

Psychopharmacologic Drugs Advisory Committee

Date, time, and place. February 6, 1995, 8:30 a.m., Parklawn Bldg., conference rooms D and E, 5600 Fishers Lane, Rockville, MD.

Type of meeting and contact person. Open public hearing, 8:30 a.m. to 9:30 a.m., unless public participation does not last that long; open committee discussion, 9:30 a.m. to 5 p.m.; Michael A. Bernstein, Center for Drug Evaluation and Research (HFD-120), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-5521, or FDA Advisory Committee Information Hotline, 1-800-741-8138 (301-443-0572 in the Washington, DC area), Psychopharmacologic Drugs Advisory Committee, code 12544.

General function of the committee. The committee reviews and evaluates data on the safety and effectiveness of marketed and investigational human drugs for use in the practice of psychiatry and related fields.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before January 30, 1995, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. The committee will discuss the safety and effectiveness of Depakote® tablets (divalproex sodium tablet), new drug application (NDA) 20-320, Abbott Laboratories, for use in the treatment of manic episodes associated with bipolar disorder.

Subcommittee Meeting of the National Task Force on Aids Drug Development/Drug Discovery Issues

Date, time, and place. February 6, 1995, 8:30 a.m., National Institutes of Health, Bldg. 31, rm. 6C-8, 9000 Rockville Pike, Bethesda, MD; and February 7, 1995, 8:30 a.m., Executive

Plaza North, conference room G, 6130 Executive Plaza Blvd., Bethesda, MD.

Type of meeting and contact person. Open subcommittee discussion, February 6, 1995, 8:30 a.m. to 4 p.m.; open public hearing, 4 p.m. to 5 p.m., unless public participation does not last that long; open subcommittee discussion, February 7, 1995, 8:30 a.m. to 4 p.m.; open public hearing, 4 p.m. to 5 p.m., unless public participation does not last that long; Jean H. McKay or Kimberley M. Miles, Office of AIDS and Special Health Issues (HF-12), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-0104, or FDA Advisory Committee Information Hotline, 1-800-741-8138 (301-443-0572 in the Washington, DC area), National Task Force on AIDS Drug Development, code 12602.

General function of the task force. The National Task Force on AIDS Drug Development shall identify any barriers and provide creative options for the rapid development and evaluation of treatments for human immunodeficiency virus (HIV) infection and its sequelae. It also advises on issues related to such barriers, and provides options for the elimination of these barriers.

Open subcommittee discussion. On February 6, 1995, the subcommittee will present, hear, and discuss issues on the use of and access to available animal models in the drug discovery/development process and examine the prospects for the development of new models for such purposes. On February 7, 1995, the subcommittee will identify mechanisms for rapid development and sharing of screening assays and to determine the feasibility of an expanded drug-screening effort, related to the identification of potential therapies for HIV disease.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the task force. Those desiring to make formal presentations should notify the contact person before February 1, 1995, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Advisory Committee on Special Studies Relating to the Possible Long-Term Health Effects of Phenoxy Herbicides and Contaminants (Ranch Hand Advisory Committee)

Date, time, and place. February 13 and 14, 1995, 9 a.m., Holiday Inn, 400 Arch St., Philadelphia, PA.

Type of meeting and contact person. Open committee discussion, February 13, 1995, 9 a.m. to 5:30 p.m.; open public hearing, February 14, 1995, 9 a.m. to 10 a.m., unless public participation does not last that long; open committee discussion, 10 a.m. to 5:30 p.m.; Ronald F. Coene, National Center for Toxicological Research (HFT-10), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-3155, or FDA Advisory Committee Information Hotline, 1-800-741-8138 (301-443-0572 in the Washington, DC area), Ranch Hand Advisory Committee, code 12560.

General function of the committee. The committee shall advise the Secretary and the Assistant Secretary for Health concerning its oversight of the conduct of the Ranch Hand Study by the Air Force and other studies in which the Secretary or the Assistant Secretary for Health believes involvement by the advisory committee is desirable.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before January 31, 1995, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their comments.

Open committee discussion. The committee will continue the review of the chapters of the draft report presenting the results of the 1992 health examination of participants in the Air Force Health Study entitled "An Epidemiologic Investigation of Health Effects in Air Force Personnel Following Exposure to Herbicides." This review will include chapters on: Neoplasia, neurology, psychology, gastrointestinal, cardiovascular, hematologic, endocrinologic, and immunologic data, as well as information on quality control, statistical methods, and covariate associations and the summary chapter on conclusions and future directions. A final agenda will be available February 6, 1995, from the contact person.